NASDAQ:CVET - Covetrus Stock Price, Forecast & News

Covetrus trades on the NASDAQ under the ticker symbol "CVET."

Covetrus Inc (NASDAQ:CVET) issued its quarterly earnings results on Tuesday, November, 12th. The company reported $0.17 EPS for the quarter, topping the Zacks' consensus estimate of $0.08 by $0.09. The company had revenue of $1.02 billion for the quarter, compared to analysts' expectations of $963.69 million. Covetrus had a positive return on equity of 4.26% and a negative net margin of 23.15%. The company's revenue was up 10.3% compared to the same quarter last year. View Covetrus' Earnings History.

Covetrus is scheduled to release their next quarterly earnings announcement on Tuesday, March 3rd 2020. View Earnings Estimates for Covetrus.

7 equities research analysts have issued 1-year price objectives for Covetrus' stock. Their forecasts range from $11.00 to $21.00. On average, they expect Covetrus' share price to reach $15.25 in the next twelve months. This suggests a possible upside of 42.4% from the stock's current price. View Analyst Price Targets for Covetrus.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Covetrus in the last year. There are currently 1 sell rating, 4 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Covetrus.

News stories about CVET stock have trended somewhat positive this week, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Covetrus earned a media sentiment score of 2.0 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the near future. View News Stories for Covetrus.

Covetrus saw a increase in short interest in the month of February. As of February 14th, there was short interest totalling 17,740,000 shares, an increase of 18.5% from the January 30th total of 14,970,000 shares. Based on an average daily volume of 1,610,000 shares, the days-to-cover ratio is currently 11.0 days. Approximately 18.2% of the shares of the stock are sold short. View Covetrus' Current Options Chain.

Some companies that are related to Covetrus include Rite Aid (RAD), 111 (YI), Petmed Express (PETS), Diplomat Pharmacy (DPLO), China Jo-Jo Drugstores (CJJD), HealthWarehouse.com (HEWA) and Dougherty's Pharmacy (MYDP).

Based on aggregate information from My MarketBeat watchlists, some companies that other Covetrus investors own include Uber Technologies (UBER), Evolent Health (EVH), Century Aluminum (CENX), IDEXX Laboratories (IDXX), PetIQ (PETQ), RealReal (REAL), SmileDirectClub (SDC), SVMK (SVMK), Canopy Growth (CGC) and Chewy (CHWY).

Covetrus' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BNP PARIBAS ASSET MANAGEMENT Holding S.A. (2.79%), State Street Corp (2.41%), First Trust Advisors LP (2.36%), Kovitz Investment Group Partners LLC (2.11%), Geode Capital Management LLC (1.02%) and Bank of New York Mellon Corp (0.96%). Company insiders that own Covetrus stock include Benjamin Shaw, Betsy S Atkins, David Christopher Dollar, Erin Powers Brennan and Timothy Ludlow. View Institutional Ownership Trends for Covetrus.

CVET stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Bank of America Corp DE, Credit Suisse AG, American International Group Inc., Gabelli Funds LLC, Man Group plc, Kovitz Investment Group Partners LLC and State Street Corp. Company insiders that have sold Covetrus company stock in the last year include Betsy S Atkins, David Christopher Dollar and Timothy Ludlow. View Insider Buying and Selling for Covetrus.

CVET stock was acquired by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Prudential Financial Inc., Principal Financial Group Inc., BNP PARIBAS ASSET MANAGEMENT Holding S.A., Palisade Capital Management LLC NJ, Russell Investments Group Ltd., Public Sector Pension Investment Board and Madison Asset Management LLC. Company insiders that have bought Covetrus stock in the last two years include Benjamin Shaw and Erin Powers Brennan. View Insider Buying and Selling for Covetrus.

Shares of CVET can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CVET stock can currently be purchased for approximately $10.71.

Covetrus has a market capitalization of $1.20 billion and generates $3.78 billion in revenue each year. Covetrus employs 5,000 workers across the globe.View Additional Information About Covetrus.

The official website for Covetrus is http://www.henryscheinvet.com/.

Covetrus' mailing address is 7 CUSTOM HOUSE STREET, PORTLAND ME, 04101. The company can be reached via phone at 888-280-2221 or via email at [email protected]